Biomarkers of cognitive decline in Parkinson's disease
Journal
Parkinsonism and Related Disorders
Journal Volume
21
Journal Issue
5
Pages
431-443
Date Issued
2015
Author(s)
Abstract
Cognitive impairment is a frequent and devastating non-motor symptom of Parkinson's disease (PD). Impaired cognition has a major impact on either quality of life or mortality in patients with PD. Notably, the rate of cognitive decline and pattern of early cognitive deficits in PD are highly variable between individuals. Given that the underlying mechanisms of cognitive decline or dementia associated with PD remain unclear, there is currently no mechanism-based treatment available. Identification of biological markers, including neuroimaging, biofluids and common genetic variants, that account for the heterogeneity of PD related cognitive decline could provide important insights into the pathological processes that underlie cognitive impairment in PD. These combined biomarker approaches will enable early diagnosis and provide indicators of cognitive progression in PD patients. This review summarizes recent advances in the development of biomarkers for cognitive impairments in PD. ? 2015 Elsevier Ltd.
SDGs
Other Subjects
alpha synuclein; amyloid beta protein; amyloid beta protein[1-40]; amyloid beta protein[1-42]; apolipoprotein E4; biological marker; fluorodeoxyglucose f 18; glucosylceramidase; iometopane i 123; methylpiperidin 4 yl propionate c 11; n fluoropropyl 2b carbomethoxy 3b (4 iodophenyl)nortropane i 123; radiopharmaceutical agent; tau protein; unclassified drug; biological marker; brain atrophy; brain blood flow; brain metabolism; cerebrospinal fluid; clinical feature; cognitive defect; dementia; diffusion tensor imaging; gene mutation; genetic marker; human; Lewy body; mild cognitive impairment; neurofibrillary tangle; neuroimaging; neuropathology; nonhuman; nuclear magnetic resonance imaging; Parkinson disease; positron emission tomography; priority journal; Review; single photon emission computer tomography; Cognition Disorders; hippocampus; metabolism; Parkinson disease; pathology; Biomarkers; Cognition Disorders; Hippocampus; Humans; Parkinson Disease
Publisher
Elsevier Ltd
Type
review